Mark Genovese
Rheumatology · Stanford, CANPI 1487711875
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $367,370 of the $404,092 with a category attached, or 90.9%. 21 manufacturers reported payments, led by Gilead at 54.3% of the total. Reporting peaked in 2019 at $229,378 and has fallen 100.0% since, to $99 in 2025. Among rheumatology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 207 payments — averaging $1952.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$220K
- Eli Lilly$62K
- Genentech, Inc.$18K
- Novartis Pharma AG$17K
- Lilly USA, LLC$16K
- EMD Serono, Inc.$13K
- plus $59K from 15 others
Across 98 payments — averaging $1923.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$49K
- Regeneron$47K
- GSK$32K
- EMD Serono, Inc.$16K
- Sanofi-aventis U.S. LLC$14K
- Roche Products Limited$12K
- plus $18K from 4 others
What the payments were for
- Consulting fees$367,37091%
- Speaking & faculty fees$3,1511%
- Travel & lodging$29,2967%
- Food & beverage$4,1261%
- Education$1490%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 51 | $219,549 |
| Eli Lilly | 68 | $61,675 |
| Genentech, Inc. | 3 | $17,645 |
| Novartis Pharma AG | 7 | $17,011 |
| Lilly USA, LLC | 10 | $15,857 |
| EMD Serono, Inc. | 3 | $13,153 |
| Novartis | 8 | $10,687 |
| UCB SA | 3 | $8,500 |
| Regeneron Healthcare Solutions, Inc. | 13 | $8,157 |
| Amgen(2 entities) | 4 | $7,229 |
| AbbVie | 15 | $7,005 |
| UCB Biosciences Inc. | 3 | $6,250 |
| GSK | 5 | $4,549 |
| Sanofi | 2 | $2,014 |
| Sanofi US Services Inc. | 1 | $1,611 |
| Samsung Bioepis Co., Ltd. | 2 | $1,200 |
| Pfizer | 1 | $940 |
| Aclaris Therapeutics, Inc. | 1 | $625 |
| Sanofi-aventis U.S. LLC | 3 | $241 |
| Medexus Pharma, Inc. | 2 | $164 |
| Genentech USA, Inc. | 2 | $31 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$404,092 in reported general payments places this provider in the 95th percentile of 808 rheumatology providers in California.
Other rheumatology in Stanford
- Sudhakar TumuluriSan Francisco$2.8M
- Ara DikranianSan Diego$2.2M
- Orrin TroumSanta Monica$1.8M
- Robin DoreTustin$1.5M
- Samy MetyasCovina$1.3M
- Rhonda LambertSan Mateo$1.1M
- William ShielMission Viejo$924K
- Mark BoriginiDowney$920K
- Adam KreitenbergTarzana$863K
- Roger KornuTustin$802K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.